A 75 year-old woman sufferred with mucosa-associated lymphoid tissue lymphoma (MALT) for many years…

Cancer History:

First diagnosis of cancer: 05/2005  Primary disease sites: MALT lymphoma

First recurrence date: 11/2012 Relapsed disease sites: the upper lobe of left lung

Therapy gone through:

Surgery: No

Chemotherapy: 7 cycles, CHOP regimen; radiotherapy: Yes, 30Gy (Stomach)

Targeted drugs: Rituximab other immunotherapy: No  others: Thalidomide

Clinical Trial Number: NCT02247609 ;  enrolled date: 16/09/2017

Interventions:

4SCAR (CD19, PSMA) after lymphodepletion with Flu-Cy

CRS Grade: 1 ; other side effects: no

Treatment response: PR     Quality of Life: improved

Progression-free interval: 1 years 10 months

Current status: Alive with disease

Disease images before and after CART treatment:

References：

1）Chang LJ, Dong LJ, Zhu J. et al. (2015) 4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass. Blood 126 (23), 264.

2）Jing HM, Chang LJ, Chen MY, Bao F, Wang J, Wang WM, Liu YY, Kuo HH, Liu YC, Dong LJ. (2015) Up-Regulation of CAR-T Cells after G-CSF and Dexamethasone Treatment in a Defuse Large B Cell Lymphoma Patient Receiving 4SCAR19 T Cell Therapy. Blood 126 (23), 5130.

3）L-J Chang, Lujia D, Liu Y-C, Tsao S-T, Li Y-C, Liu L, Gao Z, Tan X, Lu D-P, Zhang J-P, Wang J-B, Ying Y-M, Zhang L-P, Zheng H, Wang K, Zheng X-L, Wang H-X, Lai X, and Li D (2016) Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study. Blood 128 (22), 587.

4） Hao L, Li T, Chang L-J and Chen X. (2017) Adoptive immunotherapy for B-cell malignancies using CD19-targeted chimeric antigen receptor T cells: a systematic review of efficacy and safety. Curr Med Chem.

5）Chang, L.-J., Li, Y. Tu, S. et al. Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas. (2018) Blood 132:225.